Coherus Oncology, Inc.
NASDAQ:CHRSBiotechnology
+$0.03 today
- Market cap
- $63.35M
- Beta
- 0.96
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.11
Volume 2.55M
Average 1.15M
CHRS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Coherus Oncology, Inc.NASDAQ: CHRS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $20.66M fell 11.4% year over year, behind the +17.6% change in trailing-twelve-month research & development. Sequentially, it fell 31.3% from the prior quarter. Over 3 fiscal years it compounded at -19.3% a year.
Context
- Research & development amounted to 248.9% of revenue in FY2025, up 213.9 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -11.4% toward the trailing-twelve-month pace of +17.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 104.96M USD
- Year-over-year change
- +12.5%
- 4-year CAGR
- -26.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 104.96M | +12.5% |
| FY2024 | 2024-12-31 | 93.34M | -14.7% |
| FY2023 | 2023-12-31 | 109.44M | -45.1% |
| FY2022 | 2022-12-31 | 199.36M | -45.1% |
| FY2021 | 2021-12-31 | 363.11M | — |
Research & Development vs competitors
How CHRS compares with its peers on the latest reported figures
- CHRS's LTM Mar 2026 research & development of $102.32M is the 2nd highest of the 11 companies compared; the peer median is $47.33M.
- Its year-over-year change of +17.6% is the 6th highest of 11, against a peer median of +26.6%.
- Research & development amounts to 218.2% of revenue for CHRS, versus a peer median of 223.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $113.23M | +11.4% | -23.3% | 327.7% | |
| LTM Mar 2026 | $102.32M | +17.6% | -19.3% | 218.2% | |
| LTM Mar 2026 | $101.77M | -11.6% | -4.0% | 291.9% | |
| LTM Mar 2026 | $58.4M | -50.0% | -40.2% | 104.5% | |
| LTM Mar 2026 | $55.01M | +74.4% | +17.0% | 93235.6% | |
| LTM Mar 2026 | $47.7M | -0.5% | -13.2% | 61.1% | |
| LTM Mar 2026 | $46.96M | +41.8% | +36.4% | — | |
| LTM Mar 2026 | $44.75M | -15.8% | -0.4% | 154.8% | |
| LTM Sep 2026 | $23.16M | +47.2% | -19.1% | — | |
| LTM Mar 2026 | $21.52M | +58.7% | -13.4% | 28.2% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $17.59M | +68.3% | +29.6% | 902.4% |
| Peer median (excluding CHRS) | $47.33M | +26.6% | -8.6% | 223.4% | |
Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 326.55M | 211.04M | 257.24M | 266.96M | 42.17M |
| Cost of Revenue | 57.59M | 70.08M | 158.99M | 117.55M | 17.74M |
| Gross Profit | 268.96M | 140.96M | 98.25M | 149.41M | 24.43M |
| Gross Margin | 82.4% | 66.8% | 38.2% | 56.0% | 57.9% |
| Research & Development | 363.11M | 199.36M | 109.44M | 93.34M | 104.96M |
| Selling, General & Admin | 169.71M | 198.48M | 185.62M | 150.44M | 99M |
| Operating Expenses | 532.82M | 397.84M | 301.45M | 261.07M | 203.97M |
| Depreciation & Amortization | 3.45M | 3.7M | 3.79M | 5.28M | 3.92M |
| EBITDA | (260.69M) | (255.58M) | (193.94M) | 60.94M | (170.2M) |
| EBITDA Margin | -79.8% | -121.1% | -75.4% | 22.8% | -403.6% |
| Operating Income | (263.86M) | (256.88M) | (203.2M) | (111.67M) | (179.53M) |
| Operating Margin | -80.8% | -121.7% | -79.0% | -41.8% | -425.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 22.96M | 32.47M | 40.54M | 27.16M | 9M |
| Other Income / Expenses | (23.24M) | (34.87M) | (35.07M) | 140.17M | (3.59M) |
| Income Before Tax | (287.1M) | (291.75M) | (238.27M) | 28.51M | (183.12M) |
| Pre-Tax Margin | -87.9% | -138.2% | -92.6% | 10.7% | -434.2% |
| Income Tax Expense | 0 | 0 | (380K) | 0 | 0 |
| Net Income | (287.1M) | (291.75M) | (237.89M) | 28.51M | (170.29M) |
| Net Margin | -87.9% | -138.2% | -92.5% | 10.7% | -403.8% |
| EPS (Basic) | (3.81) | (3.76) | (2.53) | 0.25 | (1.45) |
| EPS (Diluted) | (3.81) | (3.76) | (2.53) | 0.25 | (1.45) |
| Weighted Avg Shares | 75.45M | 77.63M | 94.16M | 114.55M | 120.37M |
| Weighted Avg Shares (Diluted) | 75.45M | 77.63M | 94.16M | 114.83M | 120.37M |
Coherus Oncology, Inc.
NASDAQ:CHRS
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.